SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET.
康涅狄格州斯坦福，2024年11月26日（环球新闻）-- springworks therapeutics公司（纳斯达克：SWTX），是一家专注于重度罕见病和癌症的商业阶段生物制药公司，今天宣布管理层将参加于2024年12月3日星期二东部时间下午12:30在佛罗里达州科拉尔盖布尔举行的第七届evercore ISI健康大会上的炉边聊天。
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company's website at . A replay of the webcast will be available on SpringWorks' website for a limited time following the conference.
要查看现场网络直播，请访问该公司网站的投资者与媒体部分的活动与展示页面。在会后一段时间内，您可以在SpringWorks的网站上找到网络直播的重播。
About SpringWorks Therapeutics
关于springworks therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
springworks是一家商业化生物制药公司，采用精准医学方法开发和提供改变生活的药物，用于罕见疾病和癌症患者。 在美国获批用于治疗需要全身治疗的进展性腱状肿瘤成人患者的OGSIVEO（nirogacestat）是该公司首个获得FDA批准的疗法。 springworks还拥有涵盖实体肿瘤和血液系统癌症的多样化靶向疗法管线，涵盖了从临床前开发到爱文思控股临床试验的项目。 除了其全资项目外，springworks还与行业和学术界创新者达成多项合作，以释放其投资组合的全部潜力，并为有需要的患者提供更多解决方案。
For more information, visit and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
要获取更多信息，请访问 并关注@SpringWorksTx@springworks therapeutics 在X（前身为Twitter） LinkedIn，和 YouTube.
Contacts:
Investors
investors@springworkstx.com
联系人：
投资者
investors@springworkstx.com
Media
media@springworkstx.com
媒体
media@springworkstx.com
